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ORIGINAL ARTICLE

Frequency of monocyte subsets is linked to the
severity of atherosclerosis in patients with ischemic
heart disease: A case-control study
Irina Kologrivova*, Tatiana Suslova, Olga Koshelskaya, Oksana Trubacheva,
Olga Haritonova, Irina Vinnitskaya
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, Russia

Abstract
Background: Monocytes are recognized as central cells in the progression of atherosclerosis, and are subcategorized into
classical (CD14++CD16lo), intermediate (CD14++CD16hi) and non-classical (CD14+CD16hi) subsets.
Purpose: The present study aimed to assess the relationships between different subsets of monocytes, metabolic and
inﬂammatory factors in patients with stable coronary heart disease.
Methods: A total of 26 patients (both men and women) with stable ischemic heart disease (IHD) were recruited. Among
all the recruited patients, 17 patients had signiﬁcant coronary artery disease deﬁned as diameter stenosis more than 70%.
hi
Severity of CHD was assessed by the Gensini score (GS). Counts of CD14++CD16lo, CD14++CD16hi
, and CD14+CD16
monocytes were evaluated by ﬂow cytometry. Gating was veriﬁed and expression of CD163 was determined by imaging
ﬂow cytometry. Key cardiac markers, cytokines, and chemokines were detected in serum and in 24-hour-culture medium
for peripheral blood mononuclear cells (PBMC) by multiplex analysis. The Mann-Whitney U-test and Spearman's rank
correlation coefﬁcient (r) were used for statistical analysis.
Results: Patients with stenosis <70% tended to have higher frequency of CD14+CD16hi monocytes compared to patients with coronary artery stenosis >70%. The frequencies of CD163+CD14++CD16hi and CD163+CD14+CD16hi
monocytes were elevated in patients with stenosis >70%. In patients with stenosis <70%, the frequency of classical
monocytes positively correlated and the frequency of non-classical monocytes negatively correlated with the value of GS
(R ¼ 0.757; p ¼ 0.018 and R ¼ -0.757; p ¼ 0.018, respectively).
Conclusions: In patients with ischemic heart disease, the frequency of classical monocytes was directly correlated with
the severity of atherosclerosis, while the frequency of non-classical monocytes was correlated inversely. The effects of
these monocyte subsets in the development of myocardial ischemia still need to be elucidated.
Keywords: Atherosclerosis, Imaging ﬂow cytometry, Inﬂammation, Monocyte subsets

1. Background

A

therosclerosis is an underlying cause of the
development of acute cardiovascular events,
the most dangerous of which are myocardial
infarction and stroke, characterized by high
morbidity and mortality all over the world [1].
Nowadays, it is widely accepted that atherosclerosis
is associated with the development of inﬂammation
[2]. Monocytes are recognized as central cells in the

development of inﬂammation process. Their accumulation in response to injury of the endothelium
followed by the subsequent differentiation into the
macrophages and further transformation into the
foam cells is one of the primary events in the course
of atherogenesis [3, 4].
In rodent models, the monocytes with high
expression of surface marker Ly6C (Ly6Chi monocytes) predominate in the circulation and are termed
“classical” monocytes, whereas the monocytes with
low expression of this marker (Ly6Clo) are known as
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“non-classical” monocytes [5]. Ly6C marker is absent
in human monocytes. However, an alternative
approach was undertaken to categorize human
monocytes into subpopulations based on differential
expression of CD14 and CD16 molecules. Human
classical monocytes have phenotype CD14þþCD16lo,
while non-classical are CD14þCD16hi (abbreviations
such as CD14þCD16- and CD14dimCD16þ may be
used as an equivalent). Intermediate CD14þþCD16hi
monocytes are also distinguished [6].
Subpopulations of monocytes are not absolutely
discrete and are characterized by high plasticity. After
a release from the bone marrow, the classical monocytes may further differentiate into the non-classical
monocytes acquiring intermediate phenotype during
this process. Differentiation of monocytes from classical to non-classical has been shown to be dependent
upon the nuclear receptor Nr4a1 (Nur77) [7].
There exists a considerable discrepancy when it
comes to deﬁnition of the functions of monocyte
subpopulations and their input in the progression of
atherosclerosis. Numerous works demonstrated that
CD16hi monocytes (both non-classical and intermediate) are characterized by the inﬂammatory
phenotype. Indeed, they more abundantly express
surface marker CD86, TNF receptor (TNFR)-2, and
Toll-like receptor (TLR)-2, and produce higher
levels of inﬂammatory cytokines upon stimulation
compared to classical monocytes, which, on the
contrary, express high levels of surface markers
CD163 and CD93 [8, 9]. Some authors showed that
classical monocytes from normolipidemic mice
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mediate plaque regression upon recruitment and
differentiation to the anti-inﬂammatory M2 macrophages [10]. On the other hand, many works suggest
that classical CD14þþCD16lo monocytes represent
an inﬂammatory subpopulation with a causative
role in atherogenesis, whereas non-classical monocytes are considered to fulﬁll mainly patrolling
function in the vascular wall [5, 6, 11, 12].
Understanding the mechanisms, which determine
monocyte-dependent effects in atherosclerosis, may
provide the new diagnostic and therapeutic tools. This
provides a rationale for an in-depth study of the patterns of monocyte subpopulations in atherosclerosis.

2. Aim
The present study aimed to assess the relationships between the different subpopulations of
monocytes and metabolic and inﬂammatory factors
that may affect monocyte functioning and atherosclerosis severity in patients with stable coronary
heart disease.

3. Methods
3.1. Patients
The study protocol was approved by the local
Biomedical Ethics Committee of Cardiology
Research Institute (protocol #139 from November
18, 2015) as part of the fundamental interdepartmental theme #0548-2014-0018, #30 titled “Fundamental aspects of onset and development of socially

Table 1. Characteristics of patients with coronary artery disease depending on the percentage of coronary artery stenosis (Me (Q1; Q3)).
Parameter

Patients with coronary
stenosis <70% (n ¼ 9)

Patients with coronary
stenosis 70% (n ¼ 17)

p

Men/women
Age, years
GS
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
AH duration, years
DM presence
DM duration, years
Smoking
Smoking duration, years
Body mass index, kg/m2
Waist circumference, cm
Visceral adiposity index
Fasting glucose, mM
Fasting insulin, mIU/mL
HOMA
hsCRP, mg/L

4/5
65.0 (60.0; 66.0)
5.0 (0; 9.5)
120.0 (120.0; 130.0)
70.0 (70.0; 78.0)
5.0 (3.0; 15.0)
2 (22%)
0 (0; 0)
3 (33.3%)
11.5 (3.0; 20.0)
28.6 (28.0; 31.0)
98.0 (96.0; 101.0)
1.7 (1.4; 4.7)
5.2 (4.9; 5.8)
8.7 (7.5; 9.5)
1.9 (1.7; 2.3)
2.1 (1.0; 3.3)

8/9
64.0 (56.0; 65.0)
42.0 (20.0; 72.0)
125.0 (117.5; 134.5)
77.0 (64.5; 80.0)
16.0 (12.0; 30.0)
9 (52.9%)
3.0 (0.0; 14.0)
6 (35.3%)
33.0 (30.0; 40.0)
30.3 (29.0; 31.6)
102.5 (93.0; 106.0)
2.9 (2.2; 3.4)
5.9 (5.0; 6.8)
6.5 (5.2; 11.2)
2.0 (1.6; 6.6)
3.7 (1.8; 7.6)

0.613
0.525
<0.001
0.045
0.121
<0.001
0.217
0.047
1.000
0.071
0.028
0.043
0.052
0.015
0.388
0.113
0.040

GS e Gensini score; AH e arterial hypertension; DM e diabetes mellitus; HOMA e homeostatic model assessment for insulin resistance; hsCRP e high-sensitive C-reactive protein.
Bold font designates p values below 0.05.
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signiﬁcant cardio-vascular diseases, revealing of the
targets for improvement of diagnostics, treatment,
and prognosis and the mechanisms of protection”.
All patients gave the informed consent to participate
in the study. All procedures were performed in
accordance with the Helsinki Declaration and
principles of Good Clinical Practice (GCP) and
Good Laboratory Practice (GLP).
A total of 26 patients, both men and women with
stable ischemic heart disease (IHD) undergoing
coronary angiography (CA), including four patients
without coronary stenosis with myocardial ischemia
veriﬁed by the cardiac stress tests (stress echocardiography or myocardial scintigraphy) were
recruited in the study from the Department of
Atherosclerosis and Coronary Artery Disease of
Cardiology Research Institute, Tomsk NRMC.
Among all the recruited patients, 17 patients had
signiﬁcant coronary artery disease deﬁned as
diameter stenosis of more than 70%. Coronary
angiography was performed in all patients with
imaging system INNOVA (GE Medical Systems,
USA). Severity of CHD was assessed by the Gensini
score (GS). For this purpose, eight segments of the
coronary arteries were identiﬁed as follows: the left
coronary artery trunk, the anterior descending artery, the ﬁrst diagonal artery, the second diagonal
artery, the circumﬂex artery, the marginal artery, the
right coronary artery, and the posterior descending
artery. Degree of stenosis and localization of the
stenotic changes were determined with assignment
of the appropriate coefﬁcient. Patient characteristics
are presented in Table 1.
In addition, six patients without IHD were
recruited in the study to assess the frequencies of
monocytes subpopulations and lipid proﬁles.
Patients were excluded from the study if any of
the following was present: acute coronary event
such as transitory ischemic attack, acute coronary
syndrome, and acute myocardial infarction within
6 months before the study; coronary artery bypass
grafting within6 months before the study; obesity
class II and higher (body mass index (BMI) > 35);
conﬁrmed symptomatic forms of arterial hypertension; severe comorbidity (hepatic failure, kidney
failure, and oncological diseases); the presence of
gastrointestinal pathology; and refusal to participate
in the study.
All patients recruited in the study received standard antihypertensive therapy including combination of renin-angiotensin-aldosterone system
blockers (78%), indapamide retard (24%), calcium
channel blockers (52%), and beta-blockers (80%).
The majority of recruited patients (81%) received
low doses of statins (atorvastatin at a mean dose of
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15 mg and rosuvastatin at a mean dose of 7.5 mg).
Diabetes mellitus type 2 (DM2) patients received
oral glucose-lowering medications, including
biguanides (100% of DM2 patients), sulphonylurea
derivatives (50% of DM2 patients), and inhibitors of
dipeptidyl peptidase 4 (30% of DM2 patients).
Visceral adiposity index (VAI) was calculated
using the following formulas: VAI ¼ (WC/
(39.68 þ (1.88  BMI))) x (TG/1.03) x (1.31/HDL) in
male patients and VAI ¼ (WC/(36.58 þ (1.89 
BMI))) x (TG/0.81) x (1.52/HDL) in female patients:
where WC and BMI are waist circumference and
body mass index, respectively [13].
Fasting samples of peripheral blood were obtained into 4-mL heparinized tubes, 4-mL tubes
with EDTA, and 10-mL tubes without anticoagulant.
3.2. Biochemical analysis
Insulin concentrations were evaluated in serum
by enzyme-linked immunosorbent assay with
AccuBind kits (Diagnostic System Laboratories,
USA). Serum concentration of glucose was
measured by hexokinase method using analyzer
BIOSEN C-line Clinic (EKF diagnostic, Germany).
Enzyme colorimetric method was used to estimate
serum concentration of total cholesterol, triacylglycerol, and high-density lipoprotein (HDL)
cholesterol (Diakon, Russia). Concentration of lowdensity lipoprotein (LDL) cholesterol was calculated
as [LDL] ¼ [Total cholesterol] e [Triacylglycerol
(TG)] e [HDL]. Atherogenic index was calculated as
[Total cholesterol] e [HDL])/[HDL]. Glycated hemoglobin (HbA1c) content was measured by
immunoturbidimetric method (DiaSys, Germany).
Homeostatic model assessment for insulin resistance (HOMA) was calculated according to the
equation: HOMA ¼ ([fasting glucose, mmol/
l]  [fasting insulin, mIU/ml])/22,5.
3.3. Flow cytometry
Peripheral blood mononuclear cells (PBMC) were
isolated from EDTA-treated blood by centrifuging
with Histopaque 1077 (Sigma-Aldrich, USA). PBMC
were stained using the following combination of
monoclonal antibodies conjugated with the corresponding ﬂuorochromes: anti-CD14-phycoerythrin
(PE), anti-CD16-ﬂuorescein isothiocyanate (FITC),
and anti-HLA-DR-allophycocyanin (APC) (all reagents: “BD Pharmingen”, USA). Cells were
analyzed with “FACSCalibur ﬂow cytometer (BD,
USA). The percentages of classical CD14þþCD16lo,
intermediate CD14þþCD16hi, and non-classical
CD14þCD16hi monocytes were evaluated.
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Fig. 1. Subpopulations of monocytes in patients depending on the presence of coronary stenosis. A) Level of different populations of monocytes in
patients. B) Representative dot plots of different monocytes subpopulations. C) Representative images of classical (CD14þþCD16lo), non-classical
(CD14þCD16hi) and intermediate (CD14þþCD16hi) monocytes obtained during the imaging ﬂow cytometry.

3.4. Imaging ﬂow cytometry
In randomly selected patients, imaging ﬂow
cytometry was used to verify the borders for identiﬁcation of monocyte subpopulations during the
conventional ﬂow cytometric analysis (Fig. 1) and to
evaluate expression of scavenger receptor CD163.
For this purpose, cells were prepared as previously
described [3] with anti-CD163-PerCP-Cy5.5 added
to the panel of ﬂuorochromes. Cell concentration
was adjusted up to 2  107 cells/mL. Compensation
controls were prepared as cells stained with a single
ﬂuorochrome from the panel. Images of the cells
were acquired using “Amnis FlowSight” instrument
(MERCK, Millipore, USA). The compensation controls were used to create a compensation matrix,
which served as a basis for the creation of
compensated image ﬁles. Cells not in focus were
excluded from the further evaluation by gradient
RMS feature on the brightﬁeld images. Cell aggregates were excluded using scatter plot Area vs.
Aspect ratio (ratio of the shortest axis of the event to
the longest axis) on the brightﬁeld images. Only
cells with an aspect ratio above 0.6 and medium area
were selected. Gates were set on classical
CD14þþCD16lo, intermediate CD14þþCD16hi, and

non-classical CD14þCD16hi monocytes using images of the cells. Mean ﬂuorescence intensity (MFI)
of CD163 and the counts of cells expressing CD163
were assessed in each population of the monocytes
(see Fig. 2).
3.5. Multiplex analysis
We have performed an extended multiplex analysis of the cytokines, chemokines, and cardio biomarkers in serum and 24-hour PBMC culture
medium in 12 randomly selected patients. PBMC
were prepared and were either left intact or were
stimulated with 10 ug/mL lipopolysaccharide (LPS)
for 24 hours. Supernatants were collected and stored
at 40 C until the ﬁnal analysis. Key cardiac
markers (BNP, CK-MB, CXCL16, Endocan-1,
FABP3, FABP4, LIGHT, CXCL6, NT proBNP,
Oncostatin, Placental Growth Factor, and Troponin
I), cytokines and chemokines (EGF, VEGF, Eotaxin,
FGF-2, Fractalkine, G-CSF, GM-CSF, GRO, IFNa2,
IFNg, IL-1a, IL-1b, IL-1Ra, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12 (p40), IL-12
(p70), IL-13, IL-15, IL-17A/CTLA8, IP-10/CXCL10,
MCP-1/CCL2, MDC/CCL22, MIP-1a/CCL3, MIP1b/CCL4, TNFa, and TNFb/Lymphotoxin-A) were
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Fig. 2. Expression of CD163 on monocytes in patients depending on the presence of coronary stenosis. A) Frequency and mean ﬂuorescence intensity
(MFI) of CD163þ in the subpopulations of classical (CD14þþCD16lo), non-classical (CD14þCD16hi) and intermediate (CD14þþCD16hi)
monocytes. B) Representative histograms of monocytes describing expression of CD163 in different monocyte subpopulations in patient depending on
the presence of stenosis. С) Images of CD163þ monocytes obtained during imaging ﬂow cytometry.
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Table 2. Lipid proﬁles in patients with coronary artery disease and in control group (Me (Q1; Q3)).
Parameter

Control group
(no IHD) (n ¼ 6)

Patients with coronary
stenosis <70% (n ¼ 9)

Patients with
coronary stenosis
70% (n ¼ 17)

p

Total cholesterol, mM

5.03 (3.92; 6.47)

5.02 (4.44; 5.91)

3.47 (3.10; 4.70)

Triglycerides, mM

1.75 (1.17; 2.31)

1.38 (1.20; 2.74)

1.40 (0.97; 1.63)

HDL-cholesterol, mM

1.35 (1.25; 1.39)

1.15 (1.10; 1.34)

0.98 (0.78; 1.18)

LDL-cholesterol, mM

3.07 (2.15; 4.15)

3.01 (2.85; 3.23)

1.91 (1.25; 2.88)

Non-HDL-cholesterol, mM

3.68 (2.95; 5.08)

4.17 (3.40; 4.79)

2.88 (2.10; 4.17)

TG/HDL-C

1.26 (0.89; 1.58)

1.15 (1.03; 3.04)

1.46 (0.97; 1.80)

Atherogenic index

2.92 (2.65; 3.66)

3.79 (2.23; 4.25)

2.58 (2.14; 3.90)

Statins, n (%)

0

6 (66.7%)

15 (88.2%)

p1e2 ¼ 0.776
p1e3 ¼ 0.039
p2e3 ¼ 0.067
p1e2 ¼ 1.000
p1e3 ¼ 0.227
p2e3 ¼ 0.426
p1e2 ¼ 0.529
p1e3 ¼ 0.026
p2e3 ¼ 0.072
p1e2 ¼ 0.689
p1e3 ¼ 0.051
p2e3 ¼ 0.096
p1e2 ¼ 0.864
p1e3 ¼ 0.156
p2e3 ¼ 0.212
p1e2 ¼ 0.954
p1e3 ¼ 0.780
p2e3 ¼ 0.926
p1e2 ¼ 0.689
p1e3 ¼ 0.546
p2e3 ¼ 0.516
p2e3 ¼ 0.208

HDL-cholesterol e high density cholesterol; LDL-cholesterol e low-density cholesterol; TG- triglycerides.
Bold font designates p values below 0.05.

detected by Multiplex Instrument FLEXMAP 3D
(Luminex Corporation) using MILLIPLEX map
Human Cytokine/Chemokine Panel 1, Human CVD
Panel 1, and MILLIPLEX Analyst 5.1 software
(Merck KGaA, Milliplex, Darmstadt, Germany). A
total of 34 parameters were evaluated. Concentration of cardiac markers, FGF-2, Fractalkine, GRO,
IL-13, CD40L, IL-6, MCP-1, MIP-1a, and MIP-1b
were analyzed only in serum.
3.6. Statistical analysis
Analysis was performed using Statistica 10 software (StatSoft Inc., USA). The Mann-Whitney U-test
was used to estimate the signiﬁcance of differences
between groups. Spearman's rank correlation coefﬁcient (r) was used to estimate relationships between the variables. A value of p < 0.05 was
considered statistically signiﬁcant.

4. Results
Patients with coronary stenosis >70% were characterized by a higher duration of AH and DM2 (in
diabetic patients), higher values of BMI and waist
circumference, and more severe hyperglycemia
compared to patients without coronary stenosis or
with stenosis <70% (Table 1). The level of hsCRP
was elevated in this group (Table 1). Lipid proﬁles

were assessed in patients with and without IHD.
Data showed that patients with coronary stenosis
70% had lower levels of HDL-cholesterol despite
the lower levels of total cholesterol compared to
control group and patients with stenosis <70%,
which may be due to successful statin therapy
(Table 2).
Analysis of monocytes’ subpopulation revealed
that patients with stenosis <70% tended to have the
higher frequency of non-classical CD14þCD16hi
monocytes compared to patients with coronary artery stenosis >70% (Fig. 1).
At the same time, expression of CD163 on
CD14þCD16hi monocytes was higher in patients
with stenosis >70% compared to patients with stenosis <70% and control group. Both groups of patients were characterized by the higher mean
ﬂuorescence intensity (MFI) of CD163, compared to
control group (Fig. 2).
Frequency of CD163þCD14þþCD16hi monocytes
was higher in patients with stenosis >70% compared
to the control group (Fig. 2).
Results of the multiplex analysis showed that patients with stenosis >70% were characterized by the
lower levels of IL-6 in serum and the higher levels of
spontaneous IL-7 PBMC secretion and LPS-stimulated PBMC secretion of granulocyte colony-stimulating factor (G-CSF) compared to patients with
coronary stenosis <70% (Fig. 3). We did not ﬁnd any
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Fig. 3. Concentration of biomarkers in serum and culture medium in patients with IHD.
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Fig. 4. Correlations between frequency of monocyte subpopulations and clinical parameters.

signiﬁcant changes in the concentration of cardiac
markers between the patients with and without 70%
stenosis, even though patients with stenosis >70%
tended to have higher serum concentration of
FABP4 (a marker protein of adipocytes), which
probably may be explained by the elevated
anthropometric markers of adiposity in this group.

Correlation analysis revealed that the subpopulations of monocytes were associated with
different clinical parameters in patients and in
control individuals. In control group, non-classical
and intermediate monocytes were directly correlated to the ratio TG/HDL-C, whereas the frequency
of classical monocytes was reversely correlated with

Fig. 5. Correlations between cytokines, monocyte subpopulations and clinical parameters in total group of IHD patients.
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this lipid proﬁle parameter (Fig. 4). In patients with
stenosis <70%, the frequency of classical monocytes
was positively correlated and frequency of nonclassical monocytes was negatively related to the
value of the Gensini score (Fig. 4). We also found a
direct association between the frequency of intermediate monocytes and waist circumference in this
group of patients with stenosis <70% (Fig. 3). In
patients with stenosis >70%, there was a direct
correlation between the level of hsCRP and the
frequency of intermediate CD14þþCD16hi monocytes (Fig. 4).
In total group of patients, direct correlations were
observed between the concentration of granulocyte/
macrophage colony-stimulating factor (GM-CSF) in
PBMC culture medium after 24-hour LPS stimulation and GS as well as the frequency of classical
CD14þþCD16lo monocytes, whereas the frequency
of non-classical CD14þCD16hi monocytes was
inversely associated with the LPS-stimulated production of GM-CSF by PBMC (Fig. 5). The frequency of non-classical monocytes positively
correlated with the serum concentration of CXCL16,
whose role in atherosclerosis remains controversial.
The frequency of classical monocytes positively
correlated with the LPS-stimulated level of TNF-a in
24-hour PBMC culture media (Fig. 5).

5. Discussion
In our work, we showed that the absence of severe
stenosis in patients with stable IHD was associated
with the increased frequency of non-classical
CD14þCD16hi monocytes, inversely associated with
the values of GS in this group. Our study was the
ﬁrst one investigating the cohort of IHD patients
with the method of imaging ﬂow cytometry to verify
the regions during gating of monocyte subpopulations. It is an important point because the
subpopulations of classical, non-classical, and intermediate monocytes are indiscrete. An incorrect
gating may lead to false results and wrong
conclusions.
Currently there is no consensus on the role of
various subpopulations of monocytes, non-classical
monocytes in particular, in the pathogenesis of
atherosclerosis. Some articles emphasize the inﬂammatory
potential
of
the
non-classical
CD14þCD16hi monocytes [5, 8, 9]. Others regard
them rather as a patrolling monocyte subpopulation
with primary function to remove debris from the
endothelium, as well as oxidized LDL (oxLDL) and
apoptic cells [14].
On the one hand, obtained results prompt to
suspect non-classical monocytes in patients without
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stenosis and stenosis <70% to take part in the
regulation of the development of inﬂammation.
Indeed, the serum level of hsCRP was lower in
group with stenosis <70% in the presence of LPSstimulated G-CSF secretion and inverse relationships with LPS-stimulated GM-CSF secretion. We
found a direct association between CD14þCD16hi
monocytes and concentration of CXCL16, which
goes in accordance with their controversial role in
atherosclerosis. The CXCL16/CXCR16 axis is
crucially involved in the development of cardiovascular disorders [15]. CXCL16 is expressed by the
endothelial cells, smooth muscle cells, macrophages, platelets, and dendritic cells. Being cleaved
via proteolysis by ADAM-10 and ADAM-17, it may
be found in serum in its soluble form serving as a
chemoattractant for the immune cells and recruiting
them into the vascular wall [16, 17]. However,
CXCL16 exerts certain atheroprotective effects:
CXCL16 knockout mice develop bigger aortic plaques compared to wild-type animals. One possible
explanation for this controversy may be timedependent effects of CXCL16 at different stages of
atherogenesis [17]. There are also data that CD16þ
monocytes are characterized by an increased
expression of CXCL16 compared to CD16- monocytes [18]. Even more so, Slanþ (6-sulfo LacNac
residue on an O-linked carbohydrate moiety of
PSGL-1) non-classical monocytes could actively
migrate in the direction of CXCL16 playing atheroprotective role [19].
On the other hand, we suppose that the higher
levels of CD14þCD16hi monocytes cannot be
regarded as a potential biomarker of more favorable outcome in IHD patients. Development of IHD
when stenosis is absent or not severe may be
accompanied by the presence of epicardial coronary spasm or endothelial dysfunction [20, 21].
Thus, higher levels of CD14þCD16hi monocytes
may be rather a marker of endothelial dysfunction
in patients without severe coronary stenosis.
Urbanski K. et al. (2017) demonstrated a direct link
between the frequency of non-classical monocytes
and the potential of arteries to produce reactive
oxygen species [22]. Small capillaries were shown
to be enriched with non-classical monocytes where
they regulate the scavenging of the necrotic endothelial cells [23].
Lipid proﬁle in our study and TG/HDL-C ratio, in
particular, was shown to be linked to the numbers of
monocyte subpopulations only in patients without
IHD. The absence of links between these parameters in both groups of patients with IHD may be
partially explained by statin intake by the majority
of IHD patients, which could have modiﬁed lipid
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metabolism. Statin intake may also explain
discrepancy between data of lipid proﬁle and
monocyte subpopulations. According to our results,
patients with stenosis <70% had poorer control of
lipid proﬁle compared to patients with stenosis
70%, even though differences in LDL-C concentration and frequency of statin intake did not reach
the level of statistical signiﬁcance (Table 2). Meanwhile, HDL-C concentration, which is known to be
resistant to the effects of statins, was the lowest in
patients with severe atherosclerosis. Previous data
obtained by other authors showed that HDL-C
concentration of is inversely related to the frequency
of CD16þ monocytes [24, 25]. In our study, though,
it was the ratio of TG/HDL-C that had the strongest
link with the monocytes subpopulations. Saja M.F.
et al. (2015) recently showed that hypertriglyceridemia induces extravasation of non-classical Ly6Clo monocytes in mice into surrounding
tissues [26]. In our case, on the contrary, we
observed a direct correlation between TG/HDL-C
and circulating CD16þ monocytes. Probably, the
effects of lipids on monocyte redistribution may
differ between rodents and humans. Understanding
of the relationships between dyslipidemia and
monocytes functional activity still has many gaps
and requires further in-depth studies.
Another factor that may inﬂuence the functional
activity of monocytes according to our results may
be differential expression of haptoglobin-hemoglobin scavenger receptor CD163 depending on the
severity of stenosis in patients. Thus, patients with
stenosis >70% were characterized by the highest
percentage of CD163þ non-classical and intermediate monocytes. Conventionally, CD163 is considered to be a marker of anti-inﬂammatory M2
macrophages that are thought to be atheroprotective [6, 8]. However, Guo L. et al. recently
demonstrated that CD163þ macrophages are able to
induce microvascularization and increase permeability and inﬂammatory cell recruitment into
atherosclerotic plaque, which implies an existence
of quite an opposite function of these cells as it was
originally accepted [27]. CD163 has been recently
shown to serve as a scavenger-receptor for the
Tumor necrosis factor-like weak inducer of
apoptosis (TWEAK). TWEAK has proatherogenic
properties, such as induction of proinﬂammatory
cytokines and metalloproteinases production and
increase of cellular proliferation and migratory activity [28]. Soluble TWEAK (sTWEAK) decreases
while soluble CD163 (sCD163) increases together
with the severity of atherosclerosis [29]. We have
found no data on the cellular source of sCD163 in
patients with atherosclerosis. One cannot exclude
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that CD16þCD163þ monocytes play a major role in
sCD163 production.
The main limitation of our study is a low number
of recruited patients, especially in respect of a
sample size selected for multiplex analysis. This
might have had some impact on the obtained results
and can explain limited number of cytokines, chemokines, and cardiac markers that differed signiﬁcantly in patients depending on the presence of 70%
coronary stenosis.
GM-CSF is a growth factor for cells of the myeloid
lineage that has recently been shown to be involved
in the pathogenesis of atherosclerosis. Ldlr (/)
GMeCSFedeﬁcient mice produced less advanced
atherosclerosis on western diet, with decreased
macrophage and plaque apoptosis, compared to
Ldlr (/) mice with intact GM-CSF function [30].
For this reason, a strong link revealed in our study
between LPS-stimulated production of GM-CSF
and GS-values was not surprising. However, the fact
that this was accompanied by an indirect correlation
with frequency of non-classical CD14þCD16hi
monocytes, direct correlation with CD14þþCD16lo
classical monocytes, and the link between
CD14þþCD16lo cells and TNF-a production accentuates even more that classical, but not non-classical
monocytes, play the pro-inﬂammatory role during
atherogenesis. This role must take the greatest
importance at the severe stages of atherosclerosis,
judging by the correlation links between frequency
of CD14þþCD16lo monocytes and hsCRP in patients with stenosis >70%.
There are data that G-CSF prevented the development of atherosclerosis through the mobilization
of stem cells from the bone marrow in animal
models [31, 32]. In our study, we found that LPSinduced production of G-CSF was already elevated
in patients with severer atherosclerosis. Therefore,
therapeutic approaches to use G-CSF in patients
with stable IHD are unfounded. Our results go in
accordance with the work of Z. Hu et al. (2013) who
showed that G-CSF aggravates endothelial damage
and
dyslipidemia,
upregulates
endothelin-1
expression, and downregulates eNOS in the arterial
wall [33]. The prospected study by Katsaros K.M.
et al. (2015) demonstrated that serum elevation of GCSF is an independent predictor of cardiovascular
events in stable coronary artery disease [34].
An important immune regulatory cytokine, IL-7,
was also elevated in patients with severe atherosclerosis. Of note, we have observed only elevation
of the spontaneous production of IL-7 by PBMC.
PBMC produced only residual amounts of IL-7 after
24-hour LPS stimulation, which may be the sign of
their functional exhaustion. Physiological function
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of IL-7 is stimulation of T-lymphopoiesis in the
thymus and B-cell maturation [35]. However, recent
data indicate its involvement in atherogenesis as
well. Effects of IL-7 seem to be mediated by the
recruitment of monocytes into arterial plaque: IL-7
induces expression of the adhesion molecules and
monocyte chemoattractant protein-1 (MCP-1) in
vitro during incubation with the endothelial cells
[36].
The only serum biomarker that differed in patients depending on the presence of 70% stenosis
was IL-6, which, on the opposite, was elevated in
patients with less severe atherosclerosis. IL-6 plays
dualistic role in atherogenesis. On the one hand, it
stimulates development of inﬂammation and is
associated with monocytes differentiation towards
pro-inﬂammatory M1-phenotype. On the other
hand, IL-6 deﬁciency leads to the malfunctioning of
the LDL-receptor, which, in turn, may aggravate the
development of the atherosclerotic lesions [37].
There are data, that IL-6, produced by endothelial
cells during hypertension, activates transcriptional
factor STAT3 and induces transdifferentiation of the
monocytes into CD16þ cells. Reactive oxygen species and NO-deﬁciency were shown to induce IL-6
production [38]. We have already discussed that an
elevation of the non-classical monocytes in the circulation may be associated with the development of
endothelial dysfunction in patients with less severe
stenosis. Thus, IL-6 may be also involved in this
process, playing, at the same time, the regulatory
role in the development of atherosclerotic plaques.
This hypothesis requires further studies to be
undertaken.

6. Conclusions
We conclude that the frequency of non-classical
CD14þCD16hi monocytes in patients with stable
IHD is indirectly related to the severity of coronary
atherosclerosis, whereas classical CD14þþCD16lo
monocytes are directly associated with the Gensini
score and inﬂammatory biomarkers. Expression of
CD163 molecules on the intermediate and nonclassical monocytes increases in patients with stenosis >70%, which suggests the potential involvement of this molecule in the development of
atherosclerosis and associated inﬂammation. Frequency of monocyte subpopulations is linked to the
ratio of TG/HDL-C only in patients without IHD,
while monocytes are not related to the lipid proﬁle
in IHD patients receiving statin therapy. Overall,
our data shed a new light on the involvement of
monocytes subpopulations in the pathogenesis of
atherosclerosis.
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